

#2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Rachael Ann ANCLIFF et al.

Serial No.: To be assigned

Art Unit:

Filing Date: Concurrently herewith

Examiner:

For: *Morpholine Derivatives and  
Intermediates Therefor*

**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[X] Copies of the references listed on the attached form PTO-1449 as item nos. 4, 7-10, 12-16, 18-24 and 26 are enclosed

[ ] Copies of the references were submitted in parent application Serial No. \_\_\_\_\_ . (37 CFR 1.98(d))

[X] A copy of the International Search Report which issued on International Application No. PCT/EP03/03338 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 as item nos. 5-6, 11, 17 and 25, and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

[ ] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. [ ] The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

[ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[ ] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

10/509147

Atty. Docket No. PG [REDACTED] USw

DT09

PCV/PD 27 SEP 2004

C. [ ] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

[ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]

[ ] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

[ ] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[ ] A duplicate copy of this paper is attached.

Respectfully Submitted,

James P. Riek  
Attorney of Record  
Registration No. 39,009

Date: September 21, 2004  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8022  
Facsimile: (919) 483-7988

FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.

PG4790USw

SERIAL NO.

To be assigned

APPLICANT

Rachael Ann ANCLIFF et al.

10/509147

FILING DATE

Concurrently herewith

GROUP

## U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
1.	5,389,635	02/14/1995	OLSON			
2.	6,031,097	02/29/2000	HE et al.			

Continue on page

## FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
3.	EP 0243959	11/04/1987	EPO			
4.	EP 0306440	03/08/1989	EPO			X
5.	WO 95/31431	11/23/1995	WIPO			
6.	WO 95/31442	11/23/1995	WIPO			
7.	WO 95/32196	11/30/1995	WIPO			X
8.	WO 96/02534	02/01/1996	WIPO			X (Abstract)
9.	WO 96/39386	12/12/1996	WIPO			X
10.	WO 97/47601	12/18/1997	WIPO			X (Abstract)
11.	WO 98/56771	12/17/1998	WIPO			
12.	WO 99/06384	02/11/1999	WIPO			X
13.	WO 99/21848	05/06/1999	WIPO			X
14.	WO 00/18767	04/06/2000	WIPO			X
15.	WO 00/69830	11/23/2000	WIPO			X
16.	WO 01/24786	04/12/2001	WIPO			X (Abstract)
17.	WO 02/26723	04/04/2002	WIPO			

Continue on page

## OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

18.	Gonzalo et al., "The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness," <i>J. Exp. Med.</i> 188(1):157-167 (Jul. 1998).
19.	Heath et al., "Chemokine receptor usage by human eosinophils," <i>J. Clin. Invest.</i> 99(2):178-184 (1997).
20.	Jose et al., "Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation," <i>J. Exp. Med.</i> 179(3):881-887 (Mar. 1994).
21.	Lazareno et al., "Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations," <i>Br. J. Pharmacol</i> 109:1110-1119 (1995).
22.	Lloyd et al., "CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo," <i>J. Exp. Med.</i> 191(2):265-273 (Jan. 2000).
23.	Luster, "Chemokines - chemotactic cytokines that mediate inflammation," <i>New England Journal of Medicine</i> 338(7):436-445 (Feb. 1998).
24.	Motegi et al., "Interaction with secretory component stimulates effector functions of human eosinophils but not of neutrophils," <i>Journal of Immunology</i> 161:4340-4346 (1998).
25.	Sartori et al., "Synthesis and activities of net arylsulfonamido thromboxane A2 receptor antagonists," <i>European Journal of Medicinal Chemistry</i> 28(7/8):625-632 (1993).
26.	Wells et al., "Plagiarism of the host immune system: lessons about chemokine immunology from viruses," <i>Curr. Opin. Biotech.</i> 8(6):741-748 (Dec. 1997).

Continue on page

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.